These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

442 related items for PubMed ID: 31352515

  • 1. Long noncoding RNA CASC2 promotes paclitaxel resistance in breast cancer through regulation of miR-18a-5p/CDK19.
    Zheng P, Dong L, Zhang B, Dai J, Zhang Y, Wang Y, Qin S.
    Histochem Cell Biol; 2019 Oct; 152(4):281-291. PubMed ID: 31352515
    [Abstract] [Full Text] [Related]

  • 2. Circ-RNF111 contributes to paclitaxel resistance in breast cancer by elevating E2F3 expression via miR-140-5p.
    Zang H, Li Y, Zhang X, Huang G.
    Thorac Cancer; 2020 Jul; 11(7):1891-1903. PubMed ID: 32445273
    [Abstract] [Full Text] [Related]

  • 3. Long noncoding RNA MEG3 suppresses cell proliferation, migration and invasion, induces apoptosis and paclitaxel-resistance via miR-4513/PBLD axis in breast cancer cells.
    Zhu M, Wang F, Mi H, Li L, Wang J, Han M, Gu Y.
    Cell Cycle; 2020 Dec; 19(23):3277-3288. PubMed ID: 33121324
    [Abstract] [Full Text] [Related]

  • 4. Long non-coding RNA FTH1P3 activates paclitaxel resistance in breast cancer through miR-206/ABCB1.
    Wang R, Zhang T, Yang Z, Jiang C, Seng J.
    J Cell Mol Med; 2018 Sep; 22(9):4068-4075. PubMed ID: 29971911
    [Abstract] [Full Text] [Related]

  • 5. Linc00518 Contributes to Multidrug Resistance Through Regulating the MiR-199a/MRP1 Axis in Breast Cancer.
    Chang L, Hu Z, Zhou Z, Zhang H.
    Cell Physiol Biochem; 2018 Sep; 48(1):16-28. PubMed ID: 30001527
    [Abstract] [Full Text] [Related]

  • 6. Long non-coding RNA CASC2 inhibits breast cancer cell growth and metastasis through the regulation of the miR-96-5p/SYVN1 pathway.
    Gao Z, Wang H, Li H, Li M, Wang J, Zhang W, Liang X, Su D, Tang J.
    Int J Oncol; 2018 Nov; 53(5):2081-2090. PubMed ID: 30106139
    [Abstract] [Full Text] [Related]

  • 7. Long non-coding RNA UCA1 promotes the progression of paclitaxel resistance in ovarian cancer by regulating the miR-654-5p/SIK2 axis.
    Li ZY, Wang XL, Dang Y, Zhu XZ, Zhang YH, Cai BX, Zheng L.
    Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):591-603. PubMed ID: 32016960
    [Abstract] [Full Text] [Related]

  • 8. ELF1 activated long non-coding RNA CASC2 inhibits cisplatin resistance of non-small cell lung cancer via the miR-18a/IRF-2 signaling pathway.
    Xiao XH, He SY.
    Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3130-3142. PubMed ID: 32271431
    [Abstract] [Full Text] [Related]

  • 9. LncRNA AFAP1-AS1 modulates the sensitivity of paclitaxel-resistant prostate cancer cells to paclitaxel via miR-195-5p/FKBP1A axis.
    Leng W, Liu Q, Zhang S, Sun D, Guo Y.
    Cancer Biol Ther; 2020 Nov 01; 21(11):1072-1080. PubMed ID: 33138677
    [Abstract] [Full Text] [Related]

  • 10. Upregulated lncRNA CASC2 May Inhibit Malignant Melanoma Development Through Regulating miR-18a-5p/RUNX1.
    Zhang Y, Qian W, Feng F, Cao Q, Li Y, Hou Y, Zhang L, Fan J.
    Oncol Res; 2019 Feb 21; 27(3):371-377. PubMed ID: 29422114
    [Abstract] [Full Text] [Related]

  • 11. lncRNA CASC2 suppresses the growth of hemangioma cells by regulating miR-18a-5p/FBXL3 axis.
    Dai YX, Qiu MK, Wang SQ, Pan C, Wang Y, Ou JM.
    J Biol Regul Homeost Agents; 2020 Feb 21; 34(1):49-56. PubMed ID: 32138500
    [Abstract] [Full Text] [Related]

  • 12. Long non-coding RNA cancer susceptibility candidate 2 regulates the function of human fibroblast-like synoviocytes via the microRNA-18a-5p/B-cell translocation gene 3 signaling axis in rheumatoid arthritis.
    Ye Z, Wei L, Yin X, Li H, Qin G, Li S, Peng T, Liu B, Zhao S, Zhuo Q.
    Bioengineered; 2022 Feb 21; 13(2):3240-3250. PubMed ID: 35045800
    [Abstract] [Full Text] [Related]

  • 13. Long non-coding RNA CASC2 enhances cisplatin sensitivity in oral squamous cell cancer cells by the miR-31-5p/KANK1 axis.
    Wang J, Jia J, Zhou L.
    Neoplasma; 2020 Nov 21; 67(6):1279-1292. PubMed ID: 32787433
    [Abstract] [Full Text] [Related]

  • 14. SNHG5 enhances Paclitaxel sensitivity of ovarian cancer cells through sponging miR-23a.
    Lin H, Shen L, Lin Q, Dong C, Maswela B, Illahi GS, Wu X.
    Biomed Pharmacother; 2020 Mar 21; 123():109711. PubMed ID: 31884343
    [Abstract] [Full Text] [Related]

  • 15. MiR-21-5p enhances the progression and paclitaxel resistance in drug-resistant breast cancer cell lines by targeting PDCD4.
    Tao L, Wu YQ, Zhang SP.
    Neoplasma; 2019 Sep 21; 66(5):746-755. PubMed ID: 31169019
    [Abstract] [Full Text] [Related]

  • 16. CASC2 inhibits the growth, migration, and invasion of thyroid cancer cells through sponging miR-18a-5p/FIH1 axis.
    Liu QY, Gao LY, Xu L, Zhang XL, Zhang LJ, Gong XL, Luo SB, Zhao R, Cheng RC.
    Kaohsiung J Med Sci; 2021 Apr 21; 37(4):268-275. PubMed ID: 33336500
    [Abstract] [Full Text] [Related]

  • 17. MiR-18a upregulation decreases Dicer expression and confers paclitaxel resistance in triple negative breast cancer.
    Sha LY, Zhang Y, Wang W, Sui X, Liu SK, Wang T, Zhang H.
    Eur Rev Med Pharmacol Sci; 2016 Jun 21; 20(11):2201-8. PubMed ID: 27338043
    [Abstract] [Full Text] [Related]

  • 18. LncRNA CASC2 is involved in the development of chronic obstructive pulmonary disease via targeting miR-18a-5p/IGF1 axis.
    Liu P, Zhang H, Zeng H, Meng Y, Gao H, Zhang M, Zhao L.
    Ther Adv Respir Dis; 2021 Jun 21; 15():17534666211028072. PubMed ID: 34266334
    [Abstract] [Full Text] [Related]

  • 19. miR-145-5p attenuates paclitaxel resistance and suppresses the progression in drug-resistant breast cancer cell lines.
    Guan X, Guan Y.
    Neoplasma; 2020 Sep 21; 67(5):972-981. PubMed ID: 32412771
    [Abstract] [Full Text] [Related]

  • 20. MicroRNA-155-5p promotes tumor progression and contributes to paclitaxel resistance via TP53INP1 in human breast cancer.
    Li Y, Zhang L, Dong Z, Xu H, Yan L, Wang W, Yang Q, Chen C.
    Pathol Res Pract; 2021 Apr 21; 220():153405. PubMed ID: 33756128
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.